Conditional – Talk Bio

Royalty Market Accelerates with XOMA Biotech Acquisitions and OrbiMed’s Major Fundraise

1 month ago talkbio0Tagged Arenaria, Biological Factors, Biological Science Disciplines, biopharma financing, Conditional, HilleVax, Investments, LAVA, M&A, mezigitamab, OrbiMed, royalty acquisition, XOMA Royalty

royalty acquisition; XOMA Royalty; biotech M&A; OrbiMed; biopharma financing; mezigitamab; Turnstone Biologics; HilleVax; LAVA Therapeutics; contingent value rights; life sciences investment

Gilead’s Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment

7 months ago talkbio0Tagged Biliary Cholangitis, Commission, Conditional, European (ethnic group), Gilead Sciences, Primary Biliary Cholangitis, Response process, seladelpar, ursodiol

Seladelpar, Gilead Sciences, primary biliary cholangitis, PBC, European Commission, conditional marketing authorization, RESPONSE trial, ursodeoxycholic acid (UDCA)

European Commission’s Reconsideration of Translarna’s Marketing Authorization: A Critical Turning Point for Duchenne Muscular Dystrophy Treatment

11 months ago talkbio0Tagged CHMP, Commission, Conditional, Decision, Drug Approval, European (ethnic group), Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Muscular Dystrophy, Duchenne, regulatory, Translarna

Translarna, Duchenne muscular dystrophy, European Commission, EMA, CHMP, conditional marketing authorization, drug approval, regulatory decisions